You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism

Article info

Article menu
XML
Basic tumor immunology
Original research
PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism

Authors

  • Pu Sun Division of Anti-tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaUniversity of Chinese Academy of Sciences, Beijing, China PubMed articlesGoogle scholar articles
  • Xi Zhang Division of Anti-tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Rong-Jing Wang University of Chinese Academy of Sciences, Beijing, ChinaKey Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Qing-Yang Ma Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Lan Xu Division of Anti-tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Yi Wang Division of Anti-tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Hui-Ping Liao Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Hai-Long Wang Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Lan-Dian Hu Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Xiangyin Kong University of Chinese Academy of Sciences, Beijing, ChinaKey Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Jian Ding University of Chinese Academy of Sciences, Beijing, ChinaDivision of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China PubMed articlesGoogle scholar articles
  • Ling-Hua Meng Division of Anti-tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaUniversity of Chinese Academy of Sciences, Beijing, China PubMed articlesGoogle scholar articles

Citation

Sun P, Zhang X, Wang R, et al
PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism
Journal for ImmunoTherapy of Cancer 2021;9:e003093. doi: 10.1136/jitc-2021-003093
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.